Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Proton pump inhibitors

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. The Spanish acenocoumarol SmPCs, both the originator and a generic, list proton pump inhibitors, for example omeprazole, among drugs that can potentiate its anticoagulant effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its R-enantiomer, which has a much stronger anticoagulant effect (acenocoumarol SmPC, AEMPS). Omeprazole is a moderate CYP2C19 inhibitor, so it can slow the metabolism of other drugs that this enzyme metabolises and raise their levels. The omeprazole SmPC gives D-warfarin and other vitamin K antagonists as examples (omeprazole SmPC, AEMPS). For warfarin, the US omeprazole label reports increased international normalised ratio (INR) and prothrombin time in people taking warfarin with proton pump inhibitors, including omeprazole (omeprazole prescribing information, US Food and Drug Administration, FDA). The documents do not say how much the INR changes when omeprazole is combined with acenocoumarol.

Symptoms

For warfarin, the US omeprazole label states that increases in the international normalised ratio (INR) and prothrombin time may lead to abnormal bleeding and even death (omeprazole prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).

Management

No document contraindicates or prohibits this combination. When omeprazole is started or stopped, consider possible interactions with drugs metabolised by CYP2C19 (omeprazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when omeprazole is added and when it is stopped (acenocoumarol SmPCs, AEMPS). For warfarin, the US omeprazole label advises monitoring the international normalised ratio (INR) and prothrombin time and adjusting the warfarin dose if needed to keep the INR in the target range (omeprazole prescribing information, US Food and Drug Administration, FDA). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Omeprazole